REST EZ Faces Steep Competition, Single-Customer Reliance

TL;DR

**RTEZ is a highly speculative microcap with no established customer base, negative working capital, and single-customer revenue dependence; avoid.**

AI Summary

REST EZ Inc. (RTEZ) reported for the fiscal year ended March 31, 2025, that it has commenced nationwide distribution of its Rest EZ Sleep Aid Supplement soft gel capsules through wholesalers, retailers, and its website, www.RestEz.net. The company does not manufacture its product, outsourcing production to Sport Energy via a verbal agreement. RTEZ aims to expand its client base over the next twelve months through aggressive marketing, targeting wholesalers, online sales, and retail chain stores. The company faces intense competition from numerous established players with significantly greater financial resources. As of March 31, 2025, RTEZ had a working capital deficit of $3,018 and relies heavily on a single major customer for product sales and revenue. Brandon Sosa, the former CEO, was replaced by Dylan Carson on June 30, 2025, who currently devotes 28 hours per week to the company without salary or benefits, planning to increase to 40 hours and a $2,000 monthly salary upon achieving self-sufficiency.

Why It Matters

REST EZ Inc.'s reliance on a single major customer for all product sales and revenue, coupled with a working capital deficit of $3,018 as of March 31, 2025, presents significant viability concerns for investors. The company's lack of an established customer base and intense competition from larger, better-resourced competitors in the sleeping aid supplement market further compounds these risks. For employees, the absence of salaries or benefits for its sole officer, Dylan Carson, and plans to hire only 'as needed' suggests a lean, potentially unstable operational structure. Customers might benefit from the specialized soft gel capsule, but the company's precarious financial position and dependence on an unaffiliated manufacturer, Sport Energy, could impact product availability and consistency. The broader market will see if RTEZ can carve out a niche against dominant players, or if its limited resources and operational model will lead to its eventual decline.

Risk Assessment

Risk Level: high — REST EZ Inc. faces a high degree of risk due to its working capital deficit of $3,018 as of March 31, 2025, indicating insufficient capital for 12 months of operations. The company's entire product sales and revenue are derived from a single major customer, creating extreme concentration risk. Furthermore, the company's sole officer and director, Dylan Carson, has no public company experience, increasing compliance and operational risks.

Analyst Insight

Investors should exercise extreme caution and consider avoiding RTEZ stock given its high-risk profile, including a working capital deficit and reliance on a single customer. Potential investors should wait for evidence of diversified revenue streams, a positive working capital, and a more robust management structure before considering an investment.

Key Numbers

• $3,018 — Working Capital Deficit (As of March 31, 2025, indicating insufficient capital for 12 months of operations.)
• 27,537,033 — Shares Outstanding (As of March 31, 2025.)
• $80,000 — Aggregate Market Value of Non-Affiliate Common Stock (As of March 31, 2025.)
• 1 — Major Customer (Source of all product sales and revenue, creating high concentration risk.)
• 28 hours — CEO's Weekly Devotion (Dylan Carson's current time commitment to the company without salary.)
• $2,000 — Planned CEO Monthly Salary (Dylan Carson's salary once the company achieves self-sufficiency.)

Key Players & Entities

• REST EZ Inc. (company) — registrant
• Sport Energy (company) — unaffiliated outside provider and manufacturer
• Brandon Sosa (person) — former sole Director, CEO, President, Principal Executive Officer and Principal Financial Officer
• Dylan Carson (person) — current sole Director, CEO, President, Principal Executive Officer and Principal Financial Officer
• SEC (regulator) — Securities and Exchange Commission
• Sarbanes-Oxley Act of 2002 (regulator) — governance requirements
• $3,018 (dollar_amount) — working capital deficit as of March 31, 2025
• $100,000 (dollar_amount) — Mr. Sosa's potential funding if needed
• $2,000 (dollar_amount) — Dylan Carson's planned monthly salary
• 8 years (person) — Mr. Sosa's experience in health supplements

FAQ

Risk Factors

• Working Capital Deficit [high — financial]: As of March 31, 2025, the company reported a working capital deficit of $3,018. This indicates that current liabilities exceed current assets, suggesting potential difficulties in meeting short-term obligations and sustaining operations without additional capital.
• Reliance on Single Major Customer [high — financial]: The company's entire product sales and revenue are derived from a single major customer. This extreme concentration creates significant risk, as the loss of this customer would have a catastrophic impact on RTEZ's financial viability.
• Intense Competition [high — market]: RTEZ faces intense competition from numerous established players in the sleep aid market. These competitors possess significantly greater financial resources, which could hinder RTEZ's ability to gain market share and achieve its growth objectives.
• Outsourced Manufacturing Dependence [medium — operational]: The company outsources its product manufacturing to Sport Energy via a verbal agreement. This reliance on a third party for production introduces operational risks, including potential disruptions in supply, quality control issues, and the absence of a formal, long-term contract.
• Potential for Shareholder Dilution [medium — financial]: If the company needs to raise additional funds, it may do so through the sale of securities, which could result in dilution to existing shareholders. Debt financing or bank loans may also require pledging business assets.
• Product Side Effects and Safety Concerns [low — market]: The sleep aid product may have potential side effects such as stomach pain, nausea, diarrhea, and muscle cramping if taken in high doses. While a direct link to severe outcomes like kidney, liver, or heart function harm is not proven, these concerns could deter potential customers.
• New Product Market Introduction Challenges [medium — operational]: Introducing a new product nationally involves inherent risks and difficulties, including increasing brand awareness, developing an effective business plan, meeting customer standards, implementing marketing strategies, and responding to competitive pressures.

Industry Context

The sleep aid market is highly competitive, with numerous established players possessing significant financial resources. RTEZ is entering this market with a new product, facing challenges in building brand awareness and competing against larger entities. The industry is subject to FDA regulations regarding dietary supplements, which require labeling and post-market safety monitoring but do not mandate pre-market proof of safety.

Regulatory Implications

As a dietary supplement, RTEZ's product is subject to FDA regulations, primarily concerning labeling and post-market safety monitoring. While federal law does not require pre-market safety proof, the company must ensure its product adheres to all labeling requirements and is not inherently unsafe. Potential side effects, though not definitively linked to severe harm, could lead to scrutiny or consumer avoidance.

What Investors Should Do

1. Monitor customer concentration risk
2. Assess cash flow and funding needs
3. Evaluate marketing and sales strategy effectiveness
4. Observe CEO's transition and commitment

Key Dates

• 2025-03-31: Fiscal Year End — Marks the reporting period for the 10-K, revealing a working capital deficit of $3,018 and 27,537,033 shares outstanding.
• 2025-06-30: CEO Change — Brandon Sosa was replaced by Dylan Carson as CEO. Carson currently works 28 hours/week without salary, indicating a critical need for leadership and potential cost savings.

Glossary

Working Capital Deficit

A situation where a company's current liabilities exceed its current assets. It suggests a potential inability to meet short-term obligations. (RTEZ has a $3,018 working capital deficit as of March 31, 2025, highlighting a potential liquidity issue.)

Soft Gel Capsule

A type of oral dosage form where active ingredients are enclosed within a gelatin shell. (This is the form factor for RTEZ's Rest EZ Sleep Aid Supplement, impacting its manufacturing and absorption characteristics.)

Wholesalers

Intermediaries who buy large quantities of goods from manufacturers and sell them in smaller quantities to retailers. (RTEZ is actively seeking to expand its client base by targeting wholesalers for distribution of its sleep aid supplement.)

Dietary Supplement

A product intended to supplement the diet, containing one or more dietary ingredients (including vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites). (Rest EZ Sleep Aid Supplement is classified as a dietary supplement, subject to FDA labeling and safety monitoring requirements.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text. The filing focuses on the fiscal year ended March 31, 2025, and does not offer comparative data from a prior period.

Key Financial Figures

• $2,000 — he Company or more and draw a salary of $2,000 per month. 3 Table of Contents Ite
• $3,018 — 25, we had a working capital deficit of $3,018. The Company believes it does not have
• $100,000 — icated he would be able to fund another $100,000 if the company needs further assistance
• $0.010 — quotation system, the offering price of $0.010 per share for the shares of common stoc
• $0.001 — 0,000 shares of common stock, par value $0.001 per share. We may also issue additiona

Filing Documents

• restez10k033125.htm (10-K) — 357KB
• restezex31-1.htm (EX-31.1) — 9KB
• restezex31-2.htm (EX-31.2) — 10KB
• restezex32-1.htm (EX-32.1) — 4KB
• restezex32-2.htm (EX-32.2) — 4KB
• fin_001.jpg (GRAPHIC) — 45KB
• 0001185185-25-002060.txt ( ) — 2288KB
• rest-20250331.xsd (EX-101.SCH) — 17KB
• rest-20250331_cal.xml (EX-101.CAL) — 19KB
• rest-20250331_def.xml (EX-101.DEF) — 73KB
• rest-20250331_lab.xml (EX-101.LAB) — 164KB
• rest-20250331_pre.xml (EX-101.PRE) — 94KB
• restez10k033125_htm.xml (XML) — 110KB

Risk Factors

Risk Factors 4 Item 1B Unresolved Staff Comments 7 Item 1C Cybersecurity 7 Item 2

Properties

Properties 7 Item 3

Legal Proceedings

Legal Proceedings 7 Item 4 Mine Safety Disclosures 7 PART II Item 5 Market for Common Equity and Related Stockholder Matters 8 Item 6

Selected Financial Data

Selected Financial Data 8 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 9 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 12 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 13 Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 24 Item 9A

Controls and Procedures

Controls and Procedures 24 Item 9B Other Information 24 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 24 PART III Item 10 Directors, Executive Officers, and Corporate Governance 25 Item 11

Executive Compensation

Executive Compensation 26 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 27 Item 13 Certain Relationships and Related Transactions, and Director Independence 27 Item 14 Principal Accountant Fees and Services 27 PART IV Item 15 Exhibits and Financial Statement Schedules 28 Item 16 Form 10-K Summary 28

Signatures

Signatures 29 i Table of Contents PART I

Description of Business

Item 1. Description of Business. The Company was incorporated in the State of Wyoming on October 17, 2016. Rest EZ, Inc. markets a sleeping aid soft gel capsule to be sold to the general public through wholesalers and retailers, as well as online at www.RestEz.net. The Rest EZ Sleep Aid Supplement soft gel capsule is a liquid gel capsule containing soybean oil, Melatonin, gelatin, glycerin, L-glutamic Acid, yellow beeswax, purified water, L-leucine, L-arginine and lecithin. It provides faster rate with up to 100% absorption by the body. The gels are manufactured by an unaffiliated outside provider, Sport Energy. Beyond the general FDA requirement that every dietary supplement be labeled as such, either with the term "dietary supplement" or with a term that substitutes a description of the product's dietary ingredient(s) for the word "dietary" (e.g., "herbal supplement" or "calcium supplement"), and the FDA's safety monitoring responsibilities for dietary supplement firms once a dietary supplement is on the market, there are no additional FDA requirements specific to this product, and federal law does not require dietary supplements to be proven safe to FDA's satisfaction before they are marketed. Rest EZ, Inc. has commenced its full operations of having its Rest EZ Sleep Aid Supplement soft gel distributed nationwide through wholesalers and retailers, as well as online at www.RestEz.net. The Company does not manufacture its own soft gel capsule; this is outsourced to Sport Energy, an unaffiliated outside provider, who manufactures liquid gels. We plan during the next twelve months to increase our client base by aggressively marketing our product to generate: (1) wholesalers and expand our wholesale base; (2) sales on our website; and (3) sales through retail chain stores and word of mouth advertising. Rest EZ Inc. Inc. has developed a plan to market its soft gel capsule to the general public. Rest EZ, Inc. has wholesale distribution, retail, and online sales th

Risk Factors

Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this Report. Any of the following risks could harm our business, operating results and financial condition and cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. When determining whether to invest, you should also refer to the other information contained in this Report including our financial statements and the related notes thereto. (A) RISKS RELATED TO OUR BUSINESS Risks Related to Our Business If the Company needs additional money and if money is raised through the sale of our securities, the issuance of those securities could result in dilution to our existing security holders. If we raise money through debt financing or bank loans, we may be required to secure the financing with some or all of our business assets. Side effects of the product. -When taken by mouth in high doses, any sleeping aid is possibly unsafe. There is some concern that it could harm kidney, liver, or heart function. However, a connection between high doses and these negative effects has not been proven. -Sleep Aid can also cause stomach pain, nausea, diarrhea, and muscle cramping if more than the recommended amount is taken. -There is some concern that combining sleeping aids with caffeine and the herb ephedra (also called Ma Huang) might increase the chance of having serious side effects such as nausea, or stomach pain. -There is concern that sleeping aids might cause irregular heartbeat in some people, but more information is needed to know if Sleep Aids can cause this problem. It is not known how the aforementioned side effects could impact our business. We suspect some potential users of the product may decide to forego purchase of the produ

View Full Filing

View this 10-K filing on SEC EDGAR